A systematic investigation into the pathogenesis and course of Parkinson's syndrome

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

In this ambitious proposal we have assembled a group of world-leading clinical and basic science researchers possessing complementary expertise to identify and tackle the causes of Parkinsons Disease (PD). The overall goal will be a fuller understanding of the molecular pathogenesis of PD as well as improved clinical assessment of the disease prodrome. The main goals of the project are:|1. To undertake comprehensive genetic analysis of a large number of well characterised PD patients to identify rare variants and novel genes that cause and predispose to disease.|2. To perform state of the art molecular and biochemical characterisation of existing and novel PD-causing gene products and their pathways to delineate the regulation and function of these proteins.|3. To clinically dissect the prodrome of PD using a large series of at risk patients.|The consortium brings together both established PD researchers and senior researchers from other disciplines whose expertise brings new skills to this programme.||This research should yield crucial new knowledge of the molecular pathways leading to neurodegeneration and shed insight into the causation of PD|

Publications

10 25 50
 
Description 2008 - NIHR - Senior Investigator - nwood
Amount £45,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2008 
End 03/2019
 
Description 2008 - PUK - How does the PINK1 gene cause nerve cell death in Parkinson's? - aabramov
Amount £483,730 (GBP)
Funding ID F-0806 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2008 
End 05/2013
 
Description 2009 - NIHR - UCL/UCLH Comprehensive Biomedical Centre Capital Project - nwood
Amount £466,500 (GBP)
Organisation National Institute for Health Research 
Department UCLH/UCL Biomedical Research Centre
Sector Public
Country United Kingdom
Start 12/2009 
End 07/2011
 
Description 2009 - PUK - Project Grant - nwood
Amount £292,590 (GBP)
Funding ID J-0804 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2009 
End 10/2011
 
Description 2009 - PUK - What does the PINK1 gene do in nerve cells? - dalessi
Amount £84,945 (GBP)
Funding ID H-0901 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2009 
End 10/2013
 
Description 2010 - BBSRC - BBSRC Industrial CASE Partnership Grant - dalessi
Amount £75,281 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start  
 
Description 2010 - MJFF - Development of Selective LRRK2 Inhibitors - dalessi
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2010 - MJFF - Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity - dalessi
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2010 - MJFF - Investigating Signaling Pathway Dysfunction Linked to LRRK2 - plewis
Amount £357,022 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2010 
End 12/2011
 
Description 2010 - PUK - Are Lewy bodies behind dopamine nerve cell death? - mcooper
Amount £208,751 (GBP)
Funding ID G-0910 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2010 
End 07/2013
 
Description 2010 - PUK - Career development award - plewis
Amount £250,000 (GBP)
Funding ID F-1002 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2010 
End 09/2013
 
Description 2010 - PUK - How does Parkinson's spread throughout the brain? - trevesz
Amount £319,334 (GBP)
Funding ID G-1004 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2010 
End 10/2013
 
Description 2011 - AMS - Starter Grants for Clinical Lecturers - sgandhi
Amount £30,000 (GBP)
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2013
 
Description 2011 - MJFF - Analysis of LRRK2 Antibodies - dalessi
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2011 - MJFF - Generation of Monoclonal and Polyclonal Antibodies against LRRK1 - dalessi
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2011 - MJFF - Investigating Signaling Pathway Dysfunction Linked to LRRK2 - plewis
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2011 - MRC - Clinical Research Fellowship - amcneill
Amount £129,110 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2011 
End 07/2013
 
Description 2011 - MRC - Clinical Research Training Fellowship - usheerin
Amount £129,112 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2011 
End 05/2013
 
Description 2011 - NIHR - Equipment Grant - nwood
Amount £339,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 07/2011 
End 06/2012
 
Description 2011 - PUK - Can a diabetes drug also help people with Parkinson's? - mduchen
Amount £106,835 (GBP)
Funding ID G-1101 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2011 
End 07/2013
 
Description 2011 - PUK - Career development award - lalvarez
Amount £248,629 (GBP)
Funding ID F-1101 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2011 
 
Description 2011 - PUK - Filling the genetic gaps in Parkinson's - nwood
Amount £315,000 (GBP)
Funding ID G-1107 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2011 
End 11/2013
 
Description 2011 - PUK - PhD Studentship
Amount £90,580 (GBP)
Funding ID H-1006 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2011 
End 01/2014
 
Description 2011 - PUK - Should we treat Parkinson's earlier? - kbhatia
Amount £109,794 (GBP)
Funding ID G-1009 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2011 
End 03/2013
 
Description 2011 - PUK - Understanding the role of the Fbxo7 gene in Parkinson's - dalessi
Amount £145,600 (GBP)
Funding ID H-1101 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description 2011 - PUK - What is the link between Gaucher's disease and Parkinson's? - aschapira
Amount £333,229 (GBP)
Funding ID G-1104 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2011 
End 06/2012
 
Description 2011 - WT - Equipment Grant - nwood
Amount £661,636 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 12/2015
 
Description 2012 - BSF - A Role For De Novo Mutations In Parkinson's Disease - jbras
Amount £40,545 (GBP)
Organisation Bachmann-Strauss Dystonia & Parkinson Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2012 - ERC - ERC Starting Grant - awhitworth
Amount £1,268,396 (GBP)
Organisation European Research Council (ERC) 
Sector Public
Country European Union (EU)
Start  
 
Description 2012 - MJFF - Characterizing Region Specific Splice Isoforms of LRRK2 - jhardy
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2012 - MJFF - Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates - nwood
Amount £37,000 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start 06/2012 
End 06/2014
 
Description 2012 - MJFF - Development of an HTS Assay to Break the Alpha-Synuclein-Glucocerebrosidase Feedback Loop - aschapira
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2012 - MJFF - Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 Pre-clinical Monoclonal Antibodies and Characterization of Total PINK1 Pre-clinical Monoclonal Antibodies - mmuqit
Amount £1 (GBP)
Organisation Michael J Fox Foundation 
Sector Charity/Non Profit
Country United States
Start  
 
Description 2012 - PUK - A new fruit fly model of Parkinson's - awhitworth
Amount £118,380 (GBP)
Funding ID G-1201 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2012 
End 04/2014
 
Description 2012 - PUK - Fat: a new source of stem cells for Parkinson's? - jtaanman
Amount £15,500 (GBP)
Funding ID K-1201 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2012 
End 04/2013
 
Description 2012 - PUK - How does alpha-synuclein move from cell to cell? - mcooper
Amount £34,904 (GBP)
Funding ID K-1202 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2012 
End 05/2013
 
Description 2012 - PUK - Looking for genes linked with dementia with Lewy bodies - jbras
Amount £35,000 (GBP)
Funding ID K-1204 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2012 
End 04/2013
 
Description 2013 - JPND - Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease - nwood
Amount £714,181 (GBP)
Funding ID MR/L501554/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description 2013 - MRC - Centenary Award - usheerin
Amount £45,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2013 
End 01/2014
 
Description 2013 - NIHR - BRC for NIHR Rare Diseases Translational Research Collaboration: Autosomal Dominant Parkinson's disease - nwood
Amount £200,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description 2013 - PUK - How is the tau gene involved in Parkinson's? - rdesilva
Amount £34,957 (GBP)
Funding ID K-1212 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2013 
End 08/2013
 
Description 2013 - Wolfson - LWENC
Amount £20,000,000 (GBP)
Organisation The Wolfson Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2013 
End 01/2018
 
Description 2014 - AS - Postdoctoral Research Fellowship - jbras
Amount £349,994 (GBP)
Funding ID 200 
Organisation Alzheimer’s Society 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2014 
End 05/2017
 
Description 2014 - JPND - PERADES: Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focussed epigenetics and Stem cell metabolomics - jwilliams
Amount £180,526 (GBP)
Organisation JPND Research 
Sector Academic/University
Country Global
Start  
 
Description 2014 - JPND - Risk and Modifying factors in Fronto-Temporal Dementia - jhardy
Amount £576,979 (GBP)
Funding ID MR/L501542/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Title Copy number variation database 
Description Database of patients with copy number variation 
Type Of Material Improvements to research infrastructure 
Year Produced 2010 
Provided To Others? Yes  
Impact Not yet 
 
Title Healthy exomes database 
Description Database of benign genetic variability, used for filtering in exome sequencing experiments. 
Type Of Material Improvements to research infrastructure 
Year Produced 2013 
Provided To Others? Yes  
Impact Application in research. 
 
Title LRRK2 inhibitors 
Description Dario Alessi. In collaboration developed improved highly selective LRRK2 inhibitors. Elaboration of the first brain penetrable inhibitor (HG-10-102-01) that can be administered to mice by IP injection or oral gavage that effectively suppress LRRK2 in brain (Choi et al. 2012). Helped in the characterisation of by far the most selective LRRK2 inhibitor described to date (GSK2578215A) that only targets LRRK2 out of ~400 other protein kinases evaluated (Reith et al. 2012). 
Type Of Material Technology assay or reagent 
Year Produced 2012 
Provided To Others? Yes  
Impact For each of these inhibitors we have generated large supplies and have distributed these freely to the scientific community with no strings attached. 
 
Title Transgenic lines 
Description Alex Whitworth. New transgenic lines to model recently described PD genes, including; GBA (WT, N370S, L444P) and Vps35 (WT, R524W, D620N, L774M). 
Type Of Material Cell line 
Year Produced 2010 
Provided To Others? Yes  
Impact Alex Whitworth. New transgenic lines to model recently described PD genes, including; GBA (WT, N370S, L444P) and Vps35 (WT, R524W, D620N, L774M). 
 
Title Research data capture 
Description Database framework for recruitment and for entering study data via electronic forms, including directly from participants, 
Type Of Material Database/Collection of data 
Year Produced 2012 
Provided To Others? Yes  
Impact Consolidation of research studies, common data model deployed across internal and external groups, improved data capture and study management, use UCLH hospital setting. 
 
Title Research database 
Description Database for managing clinical and research datasets linked to samples. 
Type Of Material Database/Collection of data 
Year Produced 2010 
Provided To Others? Yes  
Impact Improved selection and linking, better characterised cohorts, sample conservation, less overlap and more sharing and reuse of data. 
 
Title Sample management database 
Description Database for tracking the storage and processing of research samples. 
Type Of Material Database/Collection of data 
Year Produced 2010 
Provided To Others? Yes  
Impact Improved sample management, tracking, conservation, and control. 
 
Title Variant database 
Description Database of genetic variants. 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact Lookup and validation of genetic variants across cases and research groups. 
 
Description GlaxoSmithKline (GSK) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.
Collaborator Contribution MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.
Impact MRI scanning of LRRK2 mutation carriers. Development of improved highly selective LRRK2 inhibitors. Helped characterise the most selective LRRK2 inhibitor described to date.
Start Year 2011
 
Description International Parkinson's disease consortium 
Organisation Eberhard Karls University of Tubingen
Department Neurogenetics
Country Germany 
Sector Academic/University 
PI Contribution Principal UK contributor
Collaborator Contribution Building international consortium
Impact Publication in Nature genetics and Hum Mol genetics and a further recent submission
Start Year 2009
 
Description International Parkinson's disease consortium 
Organisation National Institute on Aging
Country United States 
Sector Public 
PI Contribution Principal UK contributor
Collaborator Contribution Building international consortium
Impact Publication in Nature genetics and Hum Mol genetics and a further recent submission
Start Year 2009
 
Description Janssen Pharmaceutica 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).
Collaborator Contribution Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).
Impact Helped Janssen Pharmaceutica develop an ELISA-based assay to readily assess the impact of LRRK2 inhibitors on cells and tissues by monitoring the impact that these have on LRRK2 phosphorylation of Ser910 and Ser935 (Delbroek et al. 2013) using highly selective monoclonal antibodies we developed against these residues (Dzamko et al. 2012).
Start Year 2012
 
Description Neurobiological insights into alpha synuclein 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)
Collaborator Contribution Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)
Impact Neurobiological insights into alpha synuclein. Developed single molecule FRET to allow above studies to be undertaken. Original article in Cell 2012 Cremades et al (PMID: 22632969)
Start Year 2010
 
Description Audioslide presentation of a paper by Claudia Manzoni on how LRRK2 PD patient cells react to starvation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Audioslide presentation of a paper by Claudia Manzoni showing how fibroblast cells from people with Parkinson's disease caused by mutations in LRRK2 react to starvation.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/ukpdc/news-publications/pd-lrrk2-mutations-alter-autophagic-starvation-response
 
Description Biochemical Society meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited by the Biochemical Society to speak. Talk entitled "Unravelling the role of defective genes"; given at the conference "Beyond GWAS - a Biochemical Society meeting/workshop" on 1st July 2014 in London.
Year(s) Of Engagement Activity 2014
 
Description Biogen Idec 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact John Hardy gave a seminar on the genetics of Parkinson's Disease at biotechnology company Biogen Idec in Cambridge, Massachusetts in July 2013. Teleconference and WebEx were used in the presentation, which increased the audience to thousands.
Year(s) Of Engagement Activity 2013
 
Description Broomfield Hospital, Chelmsford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Talk on the genetics of Parkinson's Disease and Alzheimer's Disease given to medical students on 25th April 2014.
Year(s) Of Engagement Activity 2014
 
Description Cosy Science 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact John Hardy gave a talk on the genetic analysis of neurological disease to a lay audience, without any visual aids, in the function room of a pub. This was organised as part of a series of science cafés in London in May 2013.
Year(s) Of Engagement Activity 2013
 
Description Degenerating Brains public symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The "Degenerating Brains" public symposium was held on the 13th March 2013, as part of Brain Awareness Week. Around 250 people showed up to hear Professors John Hardy (UCL), Chris Shaw (KCL) and David Rubinsztein (Cambridge) discuss new discoveries in neurodegenerative diseases and how they might impact drug treatment.

Very positive feedback, increased exposure.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/ukpdc/news-publications/video-public-lecture-degenerating-brains-new-research-a...
 
Description Genetics of LRRK2 (webcast) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact http://www.ucl.ac.uk/ukpdc/news-publications/video-lrrk2-genetics-nick-wood

Providing insight into ongoing neurodegenerative disease research to lay people.
Year(s) Of Engagement Activity 2012
 
Description Material World live interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact John Hardy was interviewed live for BBC Radio 4's Material World with Quentin Cooper. This reached audiences throughout the UK and beyond. The broadcast took place on 4th April 2013.
Year(s) Of Engagement Activity 2011,2013
 
Description Neurodegenerative Diseases Initiative cross-consortium video 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Granny Marsh is 90 years old and living a wonderful life, but many her age suffer from degenerative brain diseases.

Whilst the EU spends approximately £108 billion a year supporting those with dementias, currently less than one hundredth of that is spent on research. As yet there are no cures.

That's why the Wellcome Trust and MRC are funding an international team of scientists to investigate Alzheimer's, Parkinson's and Motor Neuron Disease.



Awareness, very positive feedback.
Year(s) Of Engagement Activity 2013
URL http://youtu.be/VcIiHmkbDts
 
Description Neuromedia Corner 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Interviewed for a webcast explaining the recent advances in the genetics of Parkinson's Disease.


unknown
Year(s) Of Engagement Activity 2010
 
Description New York Times article 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release about the discovery of the new Alzheimer's disease gene (TREM2).
Year(s) Of Engagement Activity 2012
URL http://www.nytimes.com/2012/11/15/health/gene-mutation-that-hobbles-immune-response-is-linked-to-alz...
 
Description Organisation Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

Mark Cooper has hosted annual site visits from A level Biology students to learn about Parkinson's disease.
Year(s) Of Engagement Activity 2010,2011,2012,2013,2014
 
Description PUK site visit - 2011 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact Site visit from Parkinson's UK members, to provide insight into how research is being done on Parkinson's disease.

http://www.ucl.ac.uk/ukpdc/news-publications/video-lrrk2-patrick-lewis-parkinsons-uk-site-visit

Video of visit available to public.
Year(s) Of Engagement Activity 2011
 
Description PUK site visit - 2012 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

Hosted by Marta Delgado.

--
Year(s) Of Engagement Activity 2012
 
Description PUK site visit - 2013 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Site visits from the public and special interest groups to provide insight into how research is being done on Parkinson's disease.

Hosted by Andrey Abramov.

--
Year(s) Of Engagement Activity 2013
 
Description Parkinson's UK Gretschen Amphlet memorial lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The lecture was given by Dr Patrick Lewis from UCL (who is a member of the Wellcome/MRC neurodegeneration consortium) and Dr Flaviano Giorgini from the University of Leicester. The subject of the lecture was Parkinson's and the genetic revolution: from genes to treatments , and the entire lecture can be viewed on Youtube on the link below.

Increased exposure.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/ukpdc/news-publications/video-parkinsons-genes-treatments-gretschen-amphlet-mem...
 
Description Parkinson's UK Website 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Details on the finding of 5 genes which are involved in Parkinson's disease

Picked up for UK press release
Year(s) Of Engagement Activity 2011
 
Description Parkinson's UK Website 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Information disseminated to the general public about how changes in PINK1 can lead to Parkinson's disease

Interest from PD society member visits to lab about the work that is being undertaken
Year(s) Of Engagement Activity 2010
 
Description Press release of 'Genetic mutations linked to Parkinson's disease' article 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release of consortium study, published in Nature Neuroscience, showing how how genetic mutations linked to Parkinson's disease might play a key role in the death of brain cells, potentially paving the way for the development of more effective drug treatments.

News articles in Daily Mail, Herald Scotland, The Australian, and Huffington Post:

http://www.dailymail.co.uk/health/article-2389706/Parkinsons-disease-caused-genetic-defect-claim-scientists-believe-closer-treating-condition.html
http://www.heraldscotland.com/news/health/new-hope-for-brain-disease-treatment.21835795
http://www.theaustralian.com.au/news/latest-news/cell-clue-to-parkinsons-treatment/story-fn3dxix6-1226695592048
http://www.huffingtonpost.co.uk/2013/08/12/cell-targeting-treatment-parkinsons-disease_n_3742248.html



Public and media interest, increased exposure.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/ukpdc/news-publications/genetic-mutation-parkinsons-disease-link-fbxo7
 
Description Public lecture on the autophagy signaling network 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Public lecture by Francesco Cecconi, an eminent scientist in the field of autophagy and neurodegeneration, on Thursday the 25th of April 2013.
Year(s) Of Engagement Activity 2013
URL http://www.ucl.ac.uk/ukpdc/news-publications/public-lecture-london-authophagy-francesco-cecconi
 
Description Science Media Centre Expert Encounter 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact This engagement activity was in the style of an informal press briefing, on the topic "Should boxing be banned?" John Hardy was the sole member of the panel. This took place at The Wellcome Trust offices on 25th February 2013.
Year(s) Of Engagement Activity 2009,2013
 
Description TREM2 talk in Rome 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk to specialists on themes raised in recent editorial in the New England Journal at a Marguerite RoAD Investigator Meeting
Year(s) Of Engagement Activity 2014
 
Description Talk at Hebrew University-Hadassah Medical School 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk given by John Hardy on the genetic analysis of neurodegeneration to staff and students at the Hebrew University-Hadassah Medical School in Jerusalem in September 2013.
Year(s) Of Engagement Activity 2013
 
Description Talk at Takeda 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Prof John Hardy presented on the genetic analysis of neurodegenerative disease to staff at phramaceutical company Takeda in Cambridge, UK.
Year(s) Of Engagement Activity 2014
 
Description Telegraph Article 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Press release of the findings of genetic studies of Parkinson's disease

Increased interest from general public on PD genetic research
Year(s) Of Engagement Activity 2011
 
Description The Mary Lyon Centre, MRC Harwell 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Talk given by Prof John Hardy to research staff at MRC Harwell Mammalian Genetics Unit on the Harwell Science and Innovation Campus in Oxfordshire on 11th February 2014. Title: "Genetic analysis of neurodegenerative disease: towards the endgame".
Year(s) Of Engagement Activity 2014
 
Description UCL MSc Genetics of Human Disease lectures 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Various researchers including John Hardy, Helene Plun-Favreau and Nick Wood lectured to taught postgraduate students on such topics as "Cellular and Molecular Mechanisms of Disease" and "Genetics of Neurological Disease" each year between 2009 and 2015.
Year(s) Of Engagement Activity 2009,2010,2011,2012,2013
 
Description UKPDC website 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Website providing an overview of UKPDC researchers, and their collaborators, what they do, and their research output - along with news updates on activities and published papers.

www.ucl.ac.uk/ukpdc

Public interest, wide reach.
Year(s) Of Engagement Activity 2010,2011,2012,2013
 
Description Video: Advances in Genetic Understanding of Parkinson's Disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Webcast of the presentation entitled 'Advances in Genetic Understanding of Parkinson's Disease' given by Nicholas Wood (University College London, United Kingdom) presented at the Biochemical Society Hot Topic event, PINK1-Parkin Signalling in Parkinson's Disease and Beyond, held in December 2014. Video published on 8th January 2015.

Too early to tell at date of form submission.
Year(s) Of Engagement Activity 2014,2015
URL https://www.youtube.com/watch?v=sXg36yrMnc8
 
Description World Congress of Brain, Behavior and Emotions 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Interactive Keynote Lecture entitled "The puzzling genetics of neurologic and psychiatric disorders: Where are we now?". This lecture was given to an international group of scientists and the audience consisted of a few hundred people. It was held at the Palais de Congrès in Montreal in April 2014.
Year(s) Of Engagement Activity 2014
 
Description XX World Congress on Parkinson's Disease and Related Disorders 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact John Hardy was invited to give a presentation on Synuclein and Synucleinopathies. This reached an audience of researchers from across the globe. This took place in Geneva, Switzerland in December 2013.
Year(s) Of Engagement Activity 2013
 
Description XXIst World Congress of Neurology 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Plenary Talk given by John Hardy - "Impact of genetics on the field of neurology". Took place in Vienna in September 2013.
Year(s) Of Engagement Activity 2013
 
Description XXXIV Nordic Congress in Clinical Chemistry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact International conference held in Gothenburg, Sweden from 16th-19th September 2014. Talk: "Next generation sequencing in clinical diagnosis".
Year(s) Of Engagement Activity 2014